Next Phase Newsletter

A venture capital firm that was founded in 2020 with general partners based in the USA has a $100M USD fund dedicated to early-stage life science ventures from Seed to Series A.  The initial size of investment ranges from $1-5M and the firm seeks to invest in up to 10-12 early-stage life science companies worldwide.

The firm operates under a model that differs from traditional venture capital. As a way of de-risking, the firm works closely with a CRO that provides services and guidance on clinical translation and regulatory approval to therapeutics and medical device portfolio companies. The firm also works very closely with founders. As a critical criterion, the firm prefers to assign a highly experienced CEO to their portfolio company as they strongly believe in the importance of the management team. Also, the firm mostly exits through licensing to large pharma, medtech, or services companies. They are opportunistic about other exit strategies such as IPO.

The firm focuses on therapeutics, diagnostics, and digital health. The firm will not consider digital health. For therapeutics, pre-IND products of all modalities are considered. Within diagnostics, all modalities with proof of concept are considered. The firm will consider opportunities in any indication area.

The firm prefers asset-centric products and focuses on the scientific merits of the product or technology. The firm has a strict vetting process done by a highly experienced team and prefers companies with IP in place. The firm acts as a lead and co-investor and will require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage investment and development firm located in the US has more than $300 million in assets and operates under an “Evergreen” structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-5M range and the firm reserves additional funds for the subsequent funding of successful companies.

The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a fund focused on medtech investments. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and venture builder invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in immunology and oncology. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe, and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital of a manufacturing company based in Asia makes 50% of their investments in life science and healthcare and has had multiple successful exits in the past. The firm is actively looking for early-stage investment opportunities in the space. The firm prefers to invest in earlier rounds and the sweet spot is Seed to Series B. The firm is an evergreen fund. Typical initial check size ranges from $250k to half a million, but the firm is able to allocate more depending on the deal size. The firm is open to other capital structures, such as convertible notes or SAFE. The firm typically co-invests more than leads but is open to both, and it seeks opportunities globally.

The firm is most interested in therapeutics, diagnostics, medical devices and digital health and biotech R&D Services (CDMO). The firm is agnostic to subsectors and indications. Some areas of interest include technologies that support clinical study or help identify new markers or targets. In terms of stages of development, the firm is open to pre-clinical stage companies, or even companies that are in the “idea phase” as long as the technology is sound and there is some proof of concept.

There is no specific company and management team requirement. The firm will consider a board seat or observer seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm managing 2 funds makes equity investments into companies ranging from a few hundred thousand dollars to $2 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 2-3 new investments over the next 9-12 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded 2018 with headquarters in Western Europe manages two funds and is dedicated to early-stage life science ventures from Pre-seed to Series A. The initial size of investment ranges from €250k-2M, and a total of €4M when including ideally 1-3 follow-on investments. The firm partners with companies in the US and Europe.

The firm is interested in the diagnostics and digital health sectors. Within diagnostics, the firm is opportunistic and will consider technologies, services, and tools in development phases. Within digital health, the firm is opportunistic with interests including bioinformatics. The firm does not invest in clinical trials and will not consider traditional pharmaceuticals or medtech sectors. Indications of interest include oncology and neurology.

The firm highly values working with a top management team that is committed to the project. The firm acts as a lead investor and will require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.